BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer. We investigated BRCA1, XRCC1 and pol β protein expression in two cohorts (n=1602 sporadic and n=50 germ-line BRCA1 mutated) and mRNA expression in two cohorts (n=1952 and n=249). Artificial neural network analysis for BRCA1-DNA repair interacting genes was conducted in 249 tumours. Pre-clinically, BRCA1 proficient and deficient cells were DNA repair expression profiled and evaluated for synthetic lethality using ATM and DNA-PKcs inhibitors either alone or in combination with cisplatin. In human tumours, BRCA1 negativity was strongly associated with low XRCC1, and low pol β at mRNA and protein levels (p<0.0001). In patients with BRCA1 negative tumours, low XRCC1 or low pol β expression was significantly associated with poor survival in univariate and multivariate analysis compared to high XRCC1 or high pol β expressing BRCA1 negative tumours (ps<0.05). Pre-clinically, BRCA1 negative cancer cells exhibit low mRNA and low protein expression of XRCC1 and pol β. BRCA1-BER deficient cells were sensitive to ATM and DNA-PKcs inhibitor treatment either alone or in combination with cisplatin and synthetic lethality was evidenced by DNA double strand breaks accumulation, cell cycle arrest and apoptosis. We conclude that XRCC1 and pol β expression status in BRCA1 negative tumours may have prognostic significance. BRCA1-BER deficient cells could be targeted by ATM or DNA-PKcs inhibitors for personalized therapy.
INTRODUCTION
Breast Cancer Susceptibility Gene 1 (BRCA1) facilitates the efficient resolution of DNA double-strand breaks (DSBs) through homologous recombination (HR) (Caestecker and Van de Walle, 2013; Huen et al., 2010) . Cells lacking functional BRCA1 protein have impaired HR, and thus dependent on the more error-prone non-homologous end joining (NHEJ) pathway leading to chromosomal instability that drive breast cancer development (Huen et al., 2010) . In women, BRCA1 germ line mutation is associated with a 60%-70% lifetime risk of developing breast cancer (O'Donovan and Livingston, 2010) . In the more common sporadic breast cancers, epigenetic silencing of the BRCA1 promoter has been reported in up to 11%-14% of tumours (Turner et al., 2004) and a dysfunctional BRCA pathway may also contribute to a BRCAness phenotype in about 25% of cancers (Turner et al., 2004) . Base excision repair (BER) is critical for processing DNA damage caused by alkylation, oxidation, ring saturation, single strand breaks and base deamination. DNA polymerase β (pol β) and XRCC1 are key BER factors. PARP1 (poly [ADP-ribose] polymerase 1) may play an essential role in single strand break repair (SSBR), a BER-related pathway (Langelier and Pascal, 2013) . The DNA repair intermediates generated during BER/SSBR, if unrepaired, may get converted to toxic double strand breaks (DSBs) (Dianov and Hubscher, 2013) .
Emerging studies suggest a cross talk between BRCA1 and BER factors. BRCA1 mutated and basal-like breast cancer cells were found to be sensitive to oxidative DNA damage induced by H2O2 treatment. The increased sensitivity was associated with defective BER as assessed by cell based BER assay in BRCA1 deficient cells (Alli et al., 2009) . In a more recent study, BRCA1 deficient cells were sensitive to methyl methane sulfonate (alkylating agent) and functional interaction between polβ and BRCA1 was demonstrated in that study (Masaoka et al., 2013) implying a potential role for polβ in BRCA1 mediated DSB repair (Masaoka et al., 2013) . In addition, BRCA1 has also been shown to be involved in the transcriptional regulation of BER factor such as OGG1, NTH1 and APE1 (Saha et al., 2010) .
Synthetic lethality is a promising strategy for personalized cancer therapy. PARP [poly-(ADP-ribose) polymerase] inhibitors induce synthetic lethality in germ line BRCA1-deficient breast cancers and demonstrate clinical benefit in patients (Lord and Ashworth, 2008) . The data provides compelling reasons to investigate other potential synthetic lethal interactions targeting DNA repair for clinical application. Cells that are BRCA1 deficient as well as BER impaired may be reliant upon other back-up repair pathways to maintain genomic integrity and survival. ATM and DNA-PKcs play essential roles in the DNA damage response (DDR) and link DNA damage sensing to DDR effectors that regulate cell cycle progression and DNA repair (Shiloh and Ziv, 2013) . ATM, a member of the phosphatidylinositol-3-kinaselike protein kinase (PIKK) family, is a key sensor and transducer of DNA damage signalling during homologous recombination (HR) (Lee and Paull, 2007; Shiloh and Ziv, 2013) . ATM recruitment at sites of DNA damage may be dependent upon functional BRCA1 in cells . DNA-PKcs is another key member of the PIKK family and a critical component of non-homologous end-joining (NHEJ) pathway required for repair of DSBs generated throughout the cell cycle (Hill and Lee, 2010) . BRCA1 through a role in DNA end-processing may also be involved in the regulation of NHEJ (Durant and Nickoloff, 2005) .
Our hypothesis is that impaired BER in BRCA1 deficient tumours may influence prognosis.
BRCA1-BER deficient cells may be reliant upon ATM or DNA-PKcs mediated back-up pathways for cellular survival and could be targeted by synthetic lethality using inhibitors of ATM or DNA-PKcs.
MATERIALS AND METHODS

Clinical study
BRCA1 and BER protein expression analysis in Nottingham Tenovus Primary Breast
Carcinoma cohort: The study was performed in a consecutive series of 1650 patients with primary invasive breast carcinomas who were diagnosed between 1986 and 1999 and entered into the Nottingham Tenovus Primary Breast Carcinoma series described previously . Supplemental Table S1 summarizes patient demographics. Supplemental treatment data 1 summarizes various adjuvant treatments received by patients in this cohort. Table S2 ) as previously described . Supplementary Table S2 summarizes immunohistochemistry protocols for the markers tested using the Bond Max automated staining machine and Leica Bond Refine Detection kit (DS9800) according to manufacturer instructions (Leica Microsystems).
BRCA1 and BER protein expression analysis in germ line
We have recently published optimisation and specificity of XRCC1 and pol β antibody used in the current study (Abdel-Fatah et al., 2014; Sultana et al., 2013) . To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were stained and protein expression levels of the different antibodies were compared. The concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and negative (by omission of the primary antibody and IgG-matched serum) controls were included in each run.
Evaluation of immune staining:
The tumour cores were evaluated by specialist pathologists blinded to the clinicopathological characteristics of patients, in two different settings. There was excellent intra and inter-observer agreements (k > 0.8; Cohen's κ and multi-rater κ tests, respectively). Whole field inspection of the core was scored and intensities of nuclear staining were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = strong staining. The percentage of each category was estimated (0-100%). H-scores (range 0-300) were calculated by multiplying intensity of staining and percentage staining as previously described . Supplementary Table S2 summarizes cut-offs for individual markers.
Statistical analysis: Data analysis was performed using SPSS (SPSS, version 17 Chicago, IL). Where appropriate, Pearson's Chi-square, Fisher's exact, Student's t and ANOVA one way tests were used. Cumulative survival probabilities were estimated using the KaplanMeier method, and differences between survival rates were tested for significance using the log-rank test. Multivariate analysis for survival was performed using the Cox proportional hazard model. A p value < 0.05 considered significant.
Transcript levels in the METABRIC (Molecular Taxonomy of Breast Cancer
International Consortium) cohort: Investigation of the mRNA expression was performed in METABRIC cohort which refers to a set of 1980 breast cancer samples with a minimum of 5 years of clinical follow up where mRNA expression data was available (Curtis et al. Table S10 and mRNA analysis has been described previously (Bergh et al., 1995) . All microarray data are accessible at National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/, accession number: GSE4922) (Pawitan et al., 2005) . All data were normalized using the global mean method (MAS5), and probe set signal intensities were natural log transformed and scaled by adjusting the mean signal to a target value of log 500. The expression levels of the BRCA1, for the probe 204531_s_at located on the HG-U133A chip was utilized to generate the ANN based model as described previously (30) (Lancashire et al., 2010) (Lemetre, 2009) . A non-linear, ANN modelling based, data mining approach was utilised to identify the best gene probes for sample classification as described previously (30). 47,293 probes were screened for each sample in the test set (n=249). The data mining algorithm comprised a three layer multilayer perception architecture modified with a feed forward back-propagation algorithm and a sigmoidal transfer function, as previously described (Lancashire et al., 2010) . The network momentum and learning rate were respectively set as 0.1 and 0.5. Two hidden nodes were utilised. The output node was coded as 0 if a case was low BRCA1 expression (<the median) and 1 if high BRCA1 expression (>median). Inputs were ranked in ascending order based on their classification error. The top 50 predictive genes identified were merged with 150 gene probes involved in the DNA repair process and then applied to an ANN based network inference algorithm as described in earlier studies (Lemetre, 2009) . This model predicted a weighted link (direction and magnitude) between each of the gene probe markers. The 100 strongest interactions were then visualised as a map with Cytoscape (Smoot et al., 2011) . In a second bioinformatics analysis step, we sought to obtain a robust ranking of genes that are differentially expressed between the mRNA BRCA1+ cases and the mRNA BRCA1-and have high predictive power, by applying an ensemble sample classification method within a leave-one-out crossvalidation scheme. For this purpose, the 249 patient samples were first grouped into 249 different training/test set partitions, using 248 samples for the training sets and the remaining sample as the test set. For each of the 248 training sets differentially expressed genes were selected independently with the "Empirical Bayes moderated t-statistic" (Smyth, 2004 ) and used to train a machine learning model, which was evaluated based on the left-out sample (a procedure known as "external cross-validation"). To classify the left-out sample, the prediction results of four algorithms (Support Vector Machine, Random Forest, kNN and Prediction Analysis for Microarrays, with all parameters being optimised by using a grid search within a nested cross-validation) (Tibshirani et al., 2002) were combined to a majority-vote ensemble classifier as to compensate for the inevitable inherent biases and variances that exists amongst each of these machine learning algorithms. In order to rank the genes based on the cross-validation results, their frequency of occurrence in the list of significantly differentially expressed genes (p-value < 0.05) across different cross-validation cycles was recorded, and genes received higher scores the more often they had been selected.
All steps of the analysis were conducted using an in-house web-application for microarray analysis, available at www.arraymining.net. 
Evaluation of drug interaction (Combination index):
To investigate synergistic and additive activity, combination index was calculated as described previously (Berenbaum, 1981) . If D (combination index) is <1 the effect of the combination is synergistic, whereas if D=1 or D is >1 the effect is additive or antagonistic respectively. γH2AX immunocytochemistry: This assay was performed as described previously . Briefly, cells were incubated in medium containing ATM inhibitor or DNA-PKCS inhibitor for 48 hours. For cisplatin combination studies, cells were initially treated with cisplatin for 16 hours and then gently washed twice with 1X phosphate buffered saline and incubated in fresh media with or without ATM or DNA-PK inhibitors at indicated concentration for 48 hours.
Flow cytometric analyses (FACS):
Cells grown to sub-confluence were exposed to ATM or DNA-PKcs inhibitors either alone or in combination with cisplatin for 48 hours and collected by trypsinization and centrifugation (1000 rpm for 5 minutes). FACS was performed as described previously .
Annexin V flow cytometric analyses: Cells grown to sub-confluence were exposed to ATM or DNA-PKcs inhibitors either alone or in combination with cisplatin for 48 hours and collected by trypsinization and centrifugation (1000 rpm for 5 minutes). The assay was performed as described previously .
Quantitative real time PCR: RNA was extracted from cell lines using the RNeasy Mini Kit (Qiagen) and quantified using a microvolume spectrophotometer. cDNA synthesis was performed using the RT 2 First Strand Kit (Qiagen (32.3%) were negative for BRCA1 expression ( Figure 1A ). As shown in supplementary Table S3 , BRCA1 negative tumours were highly significantly associated with low XRCC1 (p<0.00001) and low polβ (p<0.000001). In the BRCA1 negative cohort we then evaluated clinicopathological associations of XRCC1 and pol β protein expression ( Figure 1A ). The data for XRCC1 and polβ are summarized in supplementary tables S4 and S5 respectively.
Although no significant associations were seen with stage, tumour grade, tumour types or pleomorphism, BRCA1 negative/ polβ low tumours were more likely to be Bcl2 negative (p=0.001) and BRCA1 negative/ XRCC1 low tumours were more likely to be p53 negative (p= 0.015).
BRCA1 negative/low XRCC1 or BRCA1 negative/low polβ tumours are associated with poor breast cancer specific survival (BCSS): BRCA1 negativity was significantly associated with poor BCSS compared to BRCA1 positive tumours (p<0.000001) ( Figure 1B ) and is consistent with previous studies showing poor prognostic significance of BRCA1 silencing in sporadic breast tumours (Hsu et al., 2013; Wu et al., 2013) . In the BRCA1 negative group we investigated the prognostic influence of XRCC1 and pol β. As shown in Figure 1C1 , BRCA1 negative/ low XRCC1 tumours had worse BCSS compared to BRCA1 negative/ high XRCC1 tumours (p=0.001). Similarly, BRCA1 negative/ low polβ tumours had worse BCSS compared to BRCA1 negative/ high polβ tumours (p=0.008) ( Figure 1D1 ).
As BRCA1 negativity is likely to be associated with ER negative tumours we conducted further analysis. In the BRCA1 negative/ER negative subgroup, low XRCC1 or low polβ remains associated with poor survival (p=0.033 and p=0.034 respectively, Figure 1C2 and 1D2). In the BRCA1 negative/ER positive subgroup, similarly, low XRCC1 was associated with poor survival (p=0.003, Figure 1C3 ) and although not significant there was trend with low polβ (p=0.121, Figure1D3). In multivariate cox regression analysis (Table 1) and BER also operated at the mRNA level we investigated the Metabric cohort (n=1920, demographics summarized in supplementary table S9) and the Uppsala cohort (n=249, demographics summarized in supplementary table S10) cohorts where mRNA expression data was available. In ER+ tumours (n=1485, metabric), low BRCA1 (n=81) was associated with poor survival compared to high BRCA1 mRNA expressing tumours (n= 1404) (p= 0.0226, Figure 2B1 ). In the low BRCA1/ER+ group, low polβ (n=66) or low XRCC1 (n=42) remains associated with poor survival (ps= 0.038 and 0.0321 respectively) compared to high polβ (n=14) or high XRCC1 (n=38) mRNA expressing tumours ( Figures 2B1 and 2B2 ). In the ER-tumours (n=435, metabric), high BRCA1 (n= 385) was associated with poor survival compared to low BRCA1 mRNA expressing tumours (n=50) (p= 0.0365, Supplementary Figure S1B ). In the low BRCA1/ER-group, low polβ (n=5) or low XRCC1 (n=17) remains associated with poor survival compared to high polβ (n=43) or high XRCC1 (n=31) mRNA expressing tumours [ps= 0.0224 and 0.0206 respectively) ( Figures 2C1 and 2C2 ). In the Uppsala cohort, low polβ mRNA (36/175 tumours) was associated with poor survival in BRCA1 low mRNA breast cancers (p=0.03, Supplementary Figure S1C ) compared to high polβ mRNA tumours (139/175 tumours). XRCC1 mRNA expression levels did not influence survival in the Uppsala cohort (Supplementary Figure S1D) .
Artificial neural network (ANN), ensemble classification and cross-validation analysis
for BRCA1 interacting DNA repair genes: The top 100 strongest are shown in Figure 2D .
The biological functions of BRCA1 interaction genes are summarized in supplementary Table   S12 . The predominant interactions with genes involved in base excision repair, nucleotide excision repair, homologous recombination, non-homologous end joining, inter-strand crosslink repair, mismatch repair and transcription is not only consistent with the previously described functions of BRCA1 (Caestecker and Van de Walle, 2013; Huen et al., 2010; Silver and Livingston, 2012) but also reveals new BRCA1 interacting genes. cell cycle arrest and induction of apoptosis. However the level of synthetic lethality effect seen with ATM inhibitor was modest compared that demonstrated previously using PARP inhibitors in BRCA1 deficient cells (Lord and Ashworth, 2008) .
Pre
Cisplatin hypersensitivity has been well established in BRCA1 deficient cells (Tassone et al., 2009 ). We investigated whether low dose cisplatin could potentiate synthetic lethality induced by KU55933. Cells were treated with a combination of low dose cisplatin (0.00001µM -0.1 µM) and KU55933 (5µM). As shown in Figure 4C1 Figure   5C3 and 5D3) and increased apoptosis ( Figure 5C4 and 5D4).
DISCUSSION
We have shown, for the first time, that BRCA1 negative tumours have significantly lower expression of XRCC1 and Polβ, a feature that was also seen in BRCA1 deficient cancer cell lines. Patients with BRCA1 negative/ low XRCC1 or BRCA1 negative /low Polβ breast tumours also have worse breast cancer specific survival including in ER+ and ER-subgroups. These new observations suggest that polβ/XRCC1 based sub-stratification may refine prognostication in BRCA1 deficient phenotypes. In addition, poor prognostic significance of pol β in a small cohort of germ-line BRCA1 mutated tumours is also consistent with a recent preclinical study linking BRCA1 and pol β in cancer cell line models (Masaoka et al., 2013) .
Moreover, the data presented here is also consistent with our previous clinical studies demonstrating poor prognostic and predictive significance of low XRCC1 (Saha et al., 2010) and NER (Hartman and Ford, 2002) suggests additional mechanisms may also operate for the observed genomic instability in BRCA1 deficient cells.
We have demonstrated that a potential synthetic lethality relationship also exists between (Lord and Ashworth, 2008) , we found that low dose cisplatin combination significantly enhanced synthetic lethality. Of note, the dose of cisplatin used in our study was 1/10 th the dose used in previous preclinical studies investigating cisplatin sensitivity in vitro in BRCA1 deficient cells (Husain et al., 1998) . We speculate that low dose cisplatin treatment generates low levels of DSBs. In cells with proficient BRCA1
and BER, despite ATM or DNA-PKcs blockade, DSBs may be rapidly repaired in back-up DNA repair pathways and cells continue to survive. The back-up repair could operate at multiple levels including the complex interactions/overlap between HR, NHEJ, alternative NHEJ (B-NHEJ) (Chapman et al., 2012; Schipler and Iliakis, 2013) , components of NER and ICL repair pathways. On the other hand, in cells with deficient BRCA1 and low BER, the associated pharmacological blockade with ATM or DNA-PKcs inhibitors may lead to DSB accumulation which beyond a threshold, may severely compromise back-up DNA repair machinery leading to DSB accumulation, cell cycle arrest and apoptosis. We have recently shown that XRCC1 deficient cells are cisplatin sensitive and ATM or DNA-PKcs inhibitors are also synthetically lethal in XRCC1 deficient cells . Given the potential role of XRCC1 in B-NHEJ (Mladenov and Iliakis, 2011) we speculate that BRCA1 deficient cells that have low XRCC1 could also have compromised B-NHEJ in addition to BER resulting in increased genomic instability and enhanced synthetic lethality with cisplatin treatment seen in the current study. Moreover, ATM or DNA-PKcs modulation has previously been shown to enhance cisplatin cytotoxicity (Dejmek et al., 2009; Yoshida et al., 2008) . Taken together, the data suggests that cisplatin combination may be more successful than ATM or DNA-PK monotherapy in BRCA1 negative tumours and would be consistent with a recent study showing enhancement of synthetic lethality with ABT-888 (PARP inhibitor) in combination with platinum chemotherapy in BRCA deficient cells (Clark et al., 2012) . 
